Divi's Lab Analysis: API Giant at ₹6,229 Eyes Growth via ₹2,000 Cr Capex
Divi's Laboratories maintains its leadership in the global API and CDMO markets with a debt-free balance sheet and an aggressive ₹2,000 crore capex plan for FY26. While short-term margins face pressure from Chinese competition, the company is pivotally positioned to capture growth in specialized segments like peptides and GLP-1 ingredients.